Bucharest mayor Nicușor Dan announced that his administration will draw inspiration from the Icelandic model to combat and ...

Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and ...

Prevention of drug-resistant tuberculosis is a global health priority. However, trials evaluating the effectiveness of treating Mycobacterium tuberculosis infection among contacts of persons with ...

Lenacapavir is already approved for use as a treatment for multi-drug resistant HIV, costing around $42,250 for the first year of therapy in the United States. Clinical trials this year showed it ...

A drug recently approved to prevent migraine may start working right away, according to a study published in the December 23, 2024, online issue of Neurology ®, the medical journal of the ...